Anand Kiran Parikh - 21 Jul 2026 Form 4 Insider Report for Faeth Therapeutics, Inc. (FTH)

Reporting relationship: President and CEO, Director
Issuer ticker: FTH
Reported as of: 21 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2026, 16:15:05 UTC
Prior SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Josiah Craver, Attorney-in-Fact

Key filing fact

Anand Kiran Parikh filed Form 4 for Faeth Therapeutics, Inc. (FTH) on 23 Jul 2026.

Key facts

This page summarizes Anand Kiran Parikh's Form 4 filing for Faeth Therapeutics, Inc. (FTH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jul 2026, 16:15.

Change

Previous filing in this sequence was filed on 24 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002111813 Primary reporting owner

Parikh Anand Kiran

Relationship: President and CEO, Director
Address: C/O FAETH THERAPEUTICS, INC., 701 TILLERY STREET #12 #1010, AUSTIN
Signature: /s/ Josiah Craver, Attorney-in-Fact
Signature date: 23 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FTH transaction Derivative

Performance-Based Stock Option (right to buy)

Award

Transaction value
Shares: +398,018
Change %
Price: $0.000000^*
Shares after: 398,018
Date: 21 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 398,018
Exercise price: $28.37
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.

Footnote F2

In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.